COVID-19 and diabetes mellitus: implications for prognosis and clinical management.
INTRODUCTION
COVID-19 is a novel coronavirus that emerged from Wuhan, China in December 2019, and within 3 months became a global pandemic.


AREAS COVERED
PubMed search of published data on COVID-19, respiratory infections, and diabetes mellitus (DM). DM associates with impairments of both cellular and humoral immunity. Early emergent global data reveal that severity of clinical outcome from COVID-19 infection (including hospitalization and admission to Intensive Care Unit [ICU]), associate with co-morbidities, prominently DM. The key principles of management of COVID-19 in patients with DM include ongoing focused outpatient management (remotely where necessary) and maintenance of good glycemic control.


EXPERT OPINION
We will remember the dawn of the third decade of the twenty-first century as a time when the world changed, the true scale and impact of which is hard for us to imagine. Like a phoenix from the ashes though, COVID-19 provides us with a great learning opportunity to renew insights into ourselves as individuals, our clinical teams, and the optimized provision of care for our patients. COVID-19 has re-shaped and re-focused our collective societal values, with a sea-changed shift from materialistic to human-centric, from self-centredness to altruism, ultimately for the betterment of patient care and the whole of society.
['Barber|Thomas M|TM|']
D000073640:Betacoronavirus D001786:Blood Glucose D000086382:COVID-19 D018352:Coronavirus Infections D003920:Diabetes Mellitus D019468:Disease Management D006801:Humans D058873:Pandemics D011024:Pneumonia, Viral D011379:Prognosis D012120:Respiration Disorders D000086402:SARS-CoV-2
COVID-19 diabetes mellitus respiratory infection immunity glycemia